Do Hedge Funds Love Impax Laboratories Inc (IPXL)?

Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. However, in this article we will take a look at their collective moves and analyze what the smart money thinks of Impax Laboratories Inc (NASDAQ:IPXL) based on that data.

Impax Laboratories Inc (NASDAQ:IPXL) has experienced a decrease in hedge fund interest lately. At the end of this article we will also compare IPXL to other stocks including CST Brands Inc (NYSE:CST), Dana Holding Corporation (NYSE:DAN), and Pebblebrook Hotel Trust (NYSE:PEB) to get a better sense of its popularity.

Today there are a lot of methods stock market investors can use to analyze their holdings. A couple of the most underrated methods are hedge fund and insider trading moves. Our researchers have shown that, historically, those who follow the best picks of the top money managers can outclass the S&P 500 by a solid amount (see the details here).

Now, we’re going to view the latest action encompassing Impax Laboratories Inc (NASDAQ:IPXL).

How have hedgies been trading Impax Laboratories Inc (NASDAQ:IPXL)?

At Q3’s end, a total of 26 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -16% from the previous quarter. With hedgies’ capital changing hands, there exists a few notable hedge fund managers who were boosting their holdings considerably (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Hound Partners, managed by Jonathan Auerbach, holds the largest position in Impax Laboratories Inc (NASDAQ:IPXL). Hound Partners has a $250.4 million position in the stock, comprising 5.4% of its 13F portfolio. Coming in second is OrbiMed Advisors, led by Samuel Isaly, holding a $234.6 million position; 2.4% of its 13F portfolio is allocated to the company. Remaining professional money managers that are bullish contain Alan Fournier’s Pennant Capital Management, Anand Parekh’s Alyeska Investment Group and David Greenspan’s Slate Path Capital.